Frontlight ResearchEarly access
Ovarian cancer trials in United States
348 trials · From ClinicalTrials.gov, checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 2Taking peopleA Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- Where
- Albuquerque, Austin, Baltimore, Bay Shore, Bethlehem, Birmingham, Chapel Hill, Charlotte, Charlottesville, Chicago, Cleveland, Columbus, Covington, Danbury, Eugene, Fairfax, Fargo, Fort Wayne, Fort Worth, Greenlawn, Greenville, Hackensack, Houston, Indianapolis, Irvine, Jackson, Jupiter, Kettering, Lake Success, Lebanon, Lexington, Los Angeles, Louisville, Miami Beach, Minneapolis, Mobile, Morgantown, New Brunswick, New Haven, New Orleans, New York, Norfolk, Norwalk, Peoria, Philadelphia, Pittsburgh, Providence, Rego Park, Reno, Roanoke, Saint Louis Park, San Antonio, San Diego, San Francisco, Santa Barbara, Shreveport, Silver Spring, Sioux Falls, Spokane, Springfield, St Louis, Teaneck, The Woodlands, Tigard, Tyler, Urbana, West Islip, Winston-Salem
- Age
- 18 years and over
- People
- 140
- Run by
- AbbVie
See details and how to joinNCT06890338 - Phase 1Taking peopleA Trial to Evaluate Safety, Tolerability, and Preliminary Efficacy of Misetionamide (GP-2250) as Monotherapy or in Combination With Gemcitabine
- Where
- Boston, Chicago, Fairway, Philadelphia
- Age
- 18 years and over
- People
- 18
- Run by
- Persevere Therapeutics Inc.
See details and how to joinNCT03854110 - No phaseTaking peopleSerum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations
- Where
- Basking Ridge, Commack, Harrison, Middletown, Montvale, New York, Uniondale
- Age
- 18 years to 44 years
- People
- 609
- Run by
- Memorial Sloan Kettering Cancer Center
See details and how to joinNCT00823654 - No phaseTaking peopleCollection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
- Where
- Bethesda
- Age
- 3 years and over
- People
- 1,100
- Run by
- National Cancer Institute (NCI)
See details and how to joinNCT01441089 - No phaseTaking peopleA Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer
- Where
- Arcadia, Duarte, Huntington Beach, Irvine, Lancaster, Long Beach, Santa Clarita, Simi Valley, South Pasadena, Upland, West Covina
- Age
- 18 years and over
- People
- 126
- Run by
- City of Hope Medical Center
See details and how to joinNCT07741968 - No phaseNot yet taking people in United StatesOvarian Cancer Liquid Biopsy for Early Assessment & Detection in Individuals With BRCA1/2 Pathogenic Variants
- Where
- Houston, New York
- Age
- 35 years and over
- People
- 70
- Run by
- Weill Medical College of Cornell University
See details and how to joinNCT07764744 - Phase 1Taking peopleA Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors
- Where
- Grand Rapids, Huntersville, Irving
- Age
- 18 years and over
- People
- 130
- Run by
- AbbVie
See details and how to joinNCT07807956 · EU 2026-526097-17-00 - Phase 3Not yet taking people in United StatesTorvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
- Where
- Albany, Anchorage, Ann Arbor, Bay Shore, Buffalo, Cleveland, Columbia, Columbus, Detroit, Greenlawn, Houston, Indianapolis, Mayfield Heights, Miami, Morgantown, New Hyde Park, New York, Norfolk, Oklahoma City, Philadelphia, Rego Park, Salt Lake City, Shreveport, Willow Grove
- Age
- 18 years and over
- People
- 600 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07816666 · EU 2026-526776-23-00 - No phaseNot yet taking people in United StatesSafety in Ovarian Cancer for Average-Risk Women - Analysis
- Where
- Austin, Waltham
- Age
- 50 years and over
- People
- 1,750
- Run by
- Mercy BioAnalytics, Inc.
See details and how to joinNCT07872644 - No phaseTaking peopleRisk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study
- Where
- Boston, Chicago, Durham, Houston, New York, Philadelphia, Rochester, Seattle, St Louis
- Age
- 18 years and over
- People
- 100
- Run by
- M.D. Anderson Cancer Center
See details and how to joinNCT05287451 - No phaseTaking peopleAlternate Day Fasting After Surgery for Patients Undergoing Chemotherapy
- Where
- Chicago
- Age
- 18 years and over
- People
- 30
- Run by
- Northwestern University
See details and how to joinNCT05990426 - Phase 1/2Taking peopleDose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
- Where
- Boston, Denver, Houston, Miami, Nashville, San Antonio
- Age
- 18 years and over
- People
- 330
- Run by
- ModeX Therapeutics, An OPKO Health Company
See details and how to joinNCT06239194 - Phase 1/2Taking peopleSMP-3124LP in Adults With Advanced Solid Tumors
- Where
- Celebration, Chicago, Columbus, Denver, Houston, Los Angeles, Nashville, San Francisco, Seattle
- Age
- 18 years and over
- People
- 120 worldwide
- Run by
- Sumitomo Pharma America, Inc.
See details and how to joinNCT06526819 - Phase 1/2Taking peopleA Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
- Where
- Denver, Detroit, New York, Orlando
- Age
- 18 years and over
- People
- 245 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT07186842 · EU 2025-522613-26-00 - Phase 1Not yet taking people in United StatesStudy of Supplemental Arginine With Chemotherapy and Immunotherapy in Platinum Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer
- Where
- Birmingham
- Age
- 18 years to 89 years
- People
- 24
- Run by
- Rebecca Arend
See details and how to joinNCT07772882 - No phaseTaking peopleEHR Intervention to Increase HBOC Genetic Testing
- Where
- New York
- Age
- 21 years to 75 years
- People
- 55
- Run by
- Columbia University
See details and how to joinNCT07876349 - Phase 1Taking peopleStudy to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
- Where
- Aurora, Charleston, Chicago, Cleveland, Denver, Duarte, Durham, Fairfax, Grand Rapids, Greenville, Houston, Nashville, New York, Providence, San Antonio, San Francisco, Sarasota, St Louis
- Age
- 18 years and over
- People
- 325 worldwide
- Run by
- AbbVie
See details and how to joinNCT06084481 · EU 2023-506227-29-00 - Phase 1/2Taking peopleA Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Where
- Albuquerque, Baltimore, Boston, Charlotte, Commack, Duarte, Houston, Irvine, New York, Pittsburgh, Santa Monica, Santa Rosa, Shreveport, St Louis
- Age
- 18 years and over
- People
- 460 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05123482 · EU 2022-502759-70-01 - Phase 1Taking peopleA Study of Sovilnesib in Subjects With Ovarian Cancer
- Where
- Atlanta, Baltimore, Birmingham, Boston, Buffalo, Charleston, Little Rock, Newport Beach, New York, Oklahoma City, Seattle
- Age
- 18 years and over
- People
- 150
- Run by
- Volastra Therapeutics, Inc.
See details and how to joinNCT06084416 - Phase 1Taking peopleOpen Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Where
- Augusta, Birmingham, Boston, Chicago, Detroit, Duarte, East Brunswick, Fairfax, Fort Worth, Houston, Lake Success, Los Angeles, Miami, Mineola, Nashville, New York, Orlando, Portland, San Antonio, San Diego, St Louis, Zion
- Age
- 18 years and over
- People
- 280
- Run by
- SystImmune Inc.
See details and how to joinNCT06293898 - Phase 1/2Taking peopleFirst-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
- Where
- Aurora, Detroit, Fairfax, Houston, Long Island City, Manhattan, Nashville, Omaha, San Antonio, Sarasota, St Louis
- Age
- 18 years and over
- People
- 218
- Run by
- Accent Therapeutics
See details and how to joinNCT06799065 - Phase 1/2Taking peoplePhase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
- Where
- Boston, Fairfax, Houston, Huntersville, New Haven, Newport Beach, San Antonio, San Francisco, Seattle
- Age
- 18 years and over
- People
- 233 worldwide
- Run by
- Ensem Therapeutics
See details and how to joinNCT06993844 - Phase 2Taking peopleA Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
- Where
- Abilene, Baton Rouge, Billings, Camden, Dallas, Detroit, Eugene, Fort Worth, Gainesville, Hilliard, Knoxville, La Jolla, Lexington, Morgantown, New York, Orlando, Philadelphia, Pinehurst, Pittsburgh, Richmond, San Antonio, Scarborough, Seattle, Sioux Falls, Solvang, St. Petersburg, Syracuse, The Woodlands, Tyler, West Palm Beach, Worcester
- Age
- 18 years and over
- People
- 400 worldwide
- Run by
- AbbVie
See details and how to joinNCT07059845 · EU 2025-521606-18-00 - Phase 1Taking peopleA Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer
- Where
- Chicago, Denver, Duarte, Fairfax, Irvine, Omaha, San Antonio, West Valley City
- Age
- 18 years and over
- People
- 285 worldwide
- Run by
- AbbVie
See details and how to joinNCT07278336 · EU 2025-522209-40-00 - Phase 1/2Taking peopleA Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.
- Where
- Chicago
- Age
- 18 years and over
- People
- 24
- Run by
- University of Chicago
See details and how to joinNCT07389239